The company has also submitted a marketing authorisation application for the drug to the European Medicines Agency. The US Food and Drug Administration (FDA) has approved Shionogi’s Fetroja ...
Fetroja® (cefiderocol) has been made available by Shionogi for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis caused by the following susceptible Gram-negative ...
The FDA has approved Fetroja® (cefiderocol; Shionogi) for the treatment of adult patients with HABP/VABP caused by susceptible Gram-negative pathogens. The Food and Drug Administration (FDA) has ...
A weekly update on new drug approvals and indications from the US Food and Drug Administration (FDA). GlaxoSmithKline’s Nucala (mepolizumab injection) has been granted a new indication for the ...
Shionogi's newest antibiotic, Fetroja, has now earned the FDA's stamp of approval, a win for patients with certain antibiotic-resistant urinary tract infections and few treatment options. But its ...
The FDA approved Shionogi & Co.’s drug, Fetroja, an antibiotic designed to treat complicated urinary tract infections. Fetroja is designed to treat complications such as kidney infections caused by ...
OSAKA, Japan--(BUSINESS WIRE)--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President & CEO: Isao Teshirogi, Ph.D.; hereafter “Shionogi”) announces new data at IDWeek 2024 from PROVE ...
OSAKA, Japan and FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi & Co., Ltd. (hereafter “Shionogi”) today announces that the Centers for Medicare & Medicaid Services (CMS) has granted a new technology ...
A retrospective chart review interim analysis demonstrated that cefiderocol achieved clinical cure in 65% and 60% of patients with Pseudomonas aeruginosa and Acinetobacter baumannii respectively, the ...
Please provide your email address to receive an email when new articles are posted on . The FDA today granted priority review to cefiderocol for the treatment of adults with hospital-acquired and ...
Analysis from a retrospective multicenter observational study showed earlier treatment resulted in a reduction of in-hospital all-cause mortality in patients with Gram-negative infections who ...
A retrospective chart review interim analysis demonstrated that cefiderocol achieved clinical cure in 65% and 60% of patients with Pseudomonas aeruginosa and Acinetobacter baumannii respectively, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results